Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma
Clinical and Molecular Hepatology · 2023
DOI: 10.3350/cmh.2022.0450 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, 2023. Verfasst von Yi-Te Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: California NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, …. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Non-alcoholic Fatty Liver Disease, Liver Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: NIH HHS, NCI NIH HHS, NIMHD NIH HHS.
Abstract (Originalsprache)
Background/Aims: Cirrhosis is the most important risk factor of hepatocellular carcinoma (HCC), and patients with cirrhosis are recommended to receive semiannual surveillance for early HCC detection. However, early cirrhosis is often asymptomatic and can go undiagnosed for years, leading to underuse of HCC surveillance in clinical practice. We characterized the frequency and associated factors of unrecognized cirrhosis in a national sample of patients with HCC from the United States.
Methods
HCC patients aged 68 years and older, diagnosed during 2011 to 2015 were included from the SEERMedicare Linked Database. If cirrhosis was diagnosed within 6 months immediately preceding HCC diagnosis or after HCC diagnosis, cases were categorized as unrecognized cirrhosis. Factors associated with unrecognized cirrhosis were identified using logistic regression analyses. Factors associated with overall survival were evaluated using Cox regression analyses.
Results
Among 5,098 HCC patients, 74.8% patients had cirrhosis. Among those with cirrhosis, 57.4% had unrecognized cirrhosis, with the highest proportion (76.3%) among those with NAFLD-related HCC. Male sex (aOR: 2.12, 95% CI: 1.83–2.46), non-Hispanic Black race (aOR: 1.93, 95% CI: 1.45–2.57), and NAFLD etiology (aOR: 4.46, 95% CI: 3.68–5.41) were associated with having unrecognized cirrhosis. Among NAFLD-related HCC patients, male sex (aOR: 2.32, 95% CI: 1.71–3.14) was associated with unrecognized cirrhosis. Unrecognized cirrhosis was independently associated with worse overall survival (aHR: 1.17, 95% CI: 1.08–1.27) compared to recognized cirrhosis.
Conclusions
Unrecognized cirrhosis is common in NAFLD-related HCC, particularly among male and Black patients, highlighting these groups as important intervention targets to improve HCC surveillance uptake and outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- California NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.
- Population Informatics Lab, School of Public Health, Texas A&M University, College Station, TX, USA.
- Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, TX, USA.
- Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
- Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
- Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Förderung
- NIH HHS
- NCI NIH HHS
- NIMHD NIH HHS
- National Institutes of Health
- American College of Gastroenterology
- Cancer Prevention and Research Institute of Texas
- Texas A&M University
- Department of Defense Peer Reviewed Cancer Research Program Career Development Award
Zitieren
APA
Lee, Y. T., Karim, M. A., Kum, H. C., Park, S., Rich, N. E., Noureddin, M., Singal, A. G., & Yang, J. D. (2023). Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2022.0450
Vancouver
Lee YT, Karim MA, Kum HC, Park S, Rich NE, Noureddin M, et al. Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma. Clinical and Molecular Hepatology. 2023. doi:10.3350/cmh.2022.0450
BibTeX
@article{Lee2023,
author = {Lee, Yi-Te and Karim, Mohammad A and Kum, Hye Chung and Park, Sulki and Rich, Nicole E and Noureddin, Mazen and Singal, Amit G and Yang, Ju Dong},
title = {Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma},
journal = {Clinical and Molecular Hepatology},
year = {2023},
doi = {10.3350/cmh.2022.0450}
}
EUVIMED